Literature DB >> 17412887

Acute myeloid leukemia with the 8q22;21q22 translocation: secondary mutational events and alternative t(8;21) transcripts.

Luke F Peterson1, Anita Boyapati, Eun-Young Ahn, Joseph R Biggs, Akiko Joo Okumura, Miao-Chia Lo, Ming Yan, Dong-Er Zhang.   

Abstract

Nonrandom and somatically acquired chromosomal translocations can be identified in nearly 50% of human acute myeloid leukemias. One common chromosomal translocation in this disease is the 8q22;21q22 translocation. It involves the AML1 (RUNX1) gene on chromosome 21 and the ETO (MTG8, RUNX1T1) gene on chromosome 8 generating the AML1-ETO fusion proteins. In this review, we survey recent advances made involving secondary mutational events and alternative t(8;21) transcripts in relation to understanding AML1-ETO leukemogenesis.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17412887      PMCID： PMC1924771          DOI： 10.1182/blood-2006-11-019265

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  103 in total

1.  The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations.

Authors:  Frederick R Appelbaum; Kenneth J Kopecky; Martin S Tallman; Marilyn L Slovak; Holly M Gundacker; Haesook T Kim; Gordon W Dewald; Hagop M Kantarjian; Sherry R Pierce; Elihu H Estey
Journal:  Br J Haematol       Date:  2006-08-25       Impact factor: 6.998

2.  The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling.

Authors:  Takayuki Ikezoe; Chie Nishioka; Taizo Tasaka; Yang Yang; Naoki Komatsu; Kazuto Togitani; H Phillip Koeffler; Hirokuni Taguchi
Journal:  Mol Cancer Ther       Date:  2006-10       Impact factor: 6.261

3.  DNA repair contributes to the drug-resistant phenotype of primary acute myeloid leukaemia cells with FLT3 internal tandem duplications and is reversed by the FLT3 inhibitor PKC412.

Authors:  C H Seedhouse; H M Hunter; B Lloyd-Lewis; A-M Massip; M Pallis; G I Carter; M Grundy; S Shang; N H Russell
Journal:  Leukemia       Date:  2006-10-26       Impact factor: 11.528

4.  Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivo.

Authors:  Guang-Biao Zhou; Hui Kang; Lan Wang; Li Gao; Ping Liu; Jun Xie; Feng-Xiang Zhang; Xiang-Qin Weng; Zhi-Xiang Shen; Jue Chen; Long-Jun Gu; Ming Yan; Dong-Er Zhang; Sai-Juan Chen; Zhen-Yi Wang; Zhu Chen
Journal:  Blood       Date:  2006-12-29       Impact factor: 22.113

5.  A leukemia fusion protein attenuates the spindle checkpoint and promotes aneuploidy.

Authors:  Anita Boyapati; Ming Yan; Luke F Peterson; Joseph R Biggs; Michelle M Le Beau; Dong-Er Zhang
Journal:  Blood       Date:  2006-12-29       Impact factor: 22.113

6.  Eriocalyxin B induces apoptosis of t(8;21) leukemia cells through NF-kappaB and MAPK signaling pathways and triggers degradation of AML1-ETO oncoprotein in a caspase-3-dependent manner.

Authors:  L Wang; W-L Zhao; J-S Yan; P Liu; H-P Sun; G-B Zhou; Z-Y Weng; W-L Wu; X-Q Weng; X-J Sun; Z Chen; H-D Sun; S-J Chen
Journal:  Cell Death Differ       Date:  2006-06-16       Impact factor: 15.828

7.  FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248).

Authors:  M M Schittenhelm; K W H Yee; J W Tyner; L McGreevey; A D Haley; A Town; D J Griffith; T Bainbridge; R M Braziel; A-M O'Farrell; J M Cherrington; M C Heinrich
Journal:  Leukemia       Date:  2006-09-14       Impact factor: 11.528

8.  A new D816 c-KIT gene mutation in refractory AML1-ETO leukemia.

Authors:  Adriana Lasa; Maria T Carricondo; Maria J Carnicer; Granada Perea; Anna Aventín; Josep F Nomdedeu
Journal:  Haematologica       Date:  2006-09       Impact factor: 9.941

Review 9.  RNA regulation and cancer development.

Authors:  Eva Scholzová; Radek Malík; Jan Sevcík; Zdenek Kleibl
Journal:  Cancer Lett       Date:  2006-05-03       Impact factor: 8.679

10.  The p21Waf1 pathway is involved in blocking leukemogenesis by the t(8;21) fusion protein AML1-ETO.

Authors:  Luke F Peterson; Ming Yan; Dong-Er Zhang
Journal:  Blood       Date:  2007-02-06       Impact factor: 22.113
View more
  38 in total

1.  RUNX1 repression-independent mechanisms of leukemogenesis by fusion genes CBFB-MYH11 and AML1-ETO (RUNX1-RUNX1T1).

Authors:  R Katherine Hyde; P Paul Liu
Journal:  J Cell Biochem       Date:  2010-08-01       Impact factor: 4.429

2.  The human SWI/SNF complex associates with RUNX1 to control transcription of hematopoietic target genes.

Authors:  Rachit Bakshi; Mohammad Q Hassan; Jitesh Pratap; Jane B Lian; Martin A Montecino; Andre J van Wijnen; Janet L Stein; Anthony N Imbalzano; Gary S Stein
Journal:  J Cell Physiol       Date:  2010-11       Impact factor: 6.384

3.  AML1/ETO cooperates with HIF1α to promote leukemogenesis through DNMT3a transactivation.

Authors:  X N Gao; F Yan; J Lin; L Gao; X L Lu; S C Wei; N Shen; J X Pang; Q Y Ning; Y Komeno; A L Deng; Y H Xu; J L Shi; Y H Li; D E Zhang; C Nervi; S J Liu; L Yu
Journal:  Leukemia       Date:  2015-03-02       Impact factor: 11.528

4.  Multivalent binding of the ETO corepressor to E proteins facilitates dual repression controls targeting chromatin and the basal transcription machinery.

Authors:  Chun Guo; Qiande Hu; Chunxia Yan; Jinsong Zhang
Journal:  Mol Cell Biol       Date:  2009-03-16       Impact factor: 4.272

Review 5.  Molecular mechanisms of ETS transcription factor-mediated tumorigenesis.

Authors:  Adwitiya Kar; Arthur Gutierrez-Hartmann
Journal:  Crit Rev Biochem Mol Biol       Date:  2013-09-25       Impact factor: 8.250

6.  Core-binding factor acute myeloid leukemia in pediatric patients enrolled in the AIEOP AML 2002/01 trial: screening and prognostic impact of c-KIT mutations.

Authors:  E Manara; V Bisio; R Masetti; V Beqiri; R Rondelli; G Menna; C Micalizzi; N Santoro; F Locatelli; G Basso; M Pigazzi
Journal:  Leukemia       Date:  2013-11-14       Impact factor: 11.528

7.  Characterization of a t(5;8)(q31;q21) translocation in a patient with mental retardation and congenital heart disease: implications for involvement of RUNX1T1 in human brain and heart development.

Authors:  Litu Zhang; Zeynep Tümer; Kjeld Møllgård; Gotthold Barbi; Eva Rossier; Eske Bendsen; Rikke Steensbjerre Møller; Reinhard Ullmann; Jian He; Nickolas Papadopoulos; Niels Tommerup; Lars Allan Larsen
Journal:  Eur J Hum Genet       Date:  2009-01-28       Impact factor: 4.246

8.  Upregulation of CD200R1 in lineage-negative leukemic cells is characteristic of AML1-ETO-positive leukemia in mice.

Authors:  Yuki Kagiyama; Jiro Kitaura; Katsuhiro Togami; Tomoyuki Uchida; Daichi Inoue; Toshihiro Matsukawa; Kumi Izawa; Kimihito C Kawabata; Yukiko Komeno; Toshihiko Oki; Fumio Nakahara; Katsuaki Sato; Hiroyuki Aburatani; Toshio Kitamura
Journal:  Int J Hematol       Date:  2012-10-25       Impact factor: 2.490

9.  Modeling interactions between leukemia-specific chromosomal changes, somatic mutations, and gene expression patterns during progression of core-binding factor leukemias.

Authors:  Dan Jones; Hui Yao; Angela Romans; Caroline Dando; Sherry Pierce; Gautam Borthakur; Amy Hamilton; Carlos Bueso-Ramos; Farhad Ravandi; Guillermo Garcia-Manero; Hagop Kantarjian
Journal:  Genes Chromosomes Cancer       Date:  2010-02       Impact factor: 5.006

10.  Attenuation of AML1-ETO cellular dysregulation correlates with increased leukemogenic potential.

Authors:  Russell C DeKelver; Ming Yan; Eun-Young Ahn; Wei-Jong Shia; Nancy A Speck; Dong-Er Zhang
Journal:  Blood       Date:  2013-02-20       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.